BG00012
Other names: BG12
In development for: Relapsing/remitting MS
Status: Phase III
Last updated: April 2007
How does it work?
BG00012 appears to have an immunomodulatory mechanism of action and is similar to a drug currently used to treat psoriasis, an autoimmune condition which affects the skin and joints.
How is it given?
BG00012 is taken orally as tablets.
Clinical studies
In a phase II study, different doses of BG00012 were compared to placebo in people with relapsing/remitting MS over 24 weeks of treatment. BG00012 significantly reduced MRI-detectable brain lesion activity. A 32% reduction in relapse rate was also observed but could not be considered significant since this measure was not included in the study design.
Phase III trials are underway.
BG00012 is being developed by Biogen Idec.
Side effects and contraindications
Not known.
References
No published results at present.
- Other oral treatments for relapsing/remitting MS
- BG00012
- Cladribine
- Fingolimod
- Laquinimod
- Teriflunomide
